Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.62 |
| ▸ | MIF | P14174 | 2/20 | 0.60 |
| ▸ | METAP1 | P53582 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.59 |
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | BACE1 | P56817 | 3/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364741 | 1.00 | MAOB (0.65) | MAOBCYP19A1MIFMETAP1MAOA | |
| SCHEMBL4808965 | 0.92 | MIF (0.61) | MAOBCYP19A1MIFMETAP1MAOA | |
| SCHEMBL4808970 | 0.92 | MIF (0.61) | MAOBCYP19A1MIFMETAP1MAOA | |
| SCHEMBL6361514 | 0.86 | MIF (0.67) | CYP19A1MIFABCB1HSP90AA1CYP26A1 | |
| SCHEMBL12760787 | 0.86 | MIF (0.67) | CYP19A1MIFABCB1HSP90AA1CYP26A1 | |
| SCHEMBL30413650 | 0.81 | MAOB (0.84) | MAOBCYP19A1MIFMAOAACHE | |
| SCHEMBL28927416 | 0.81 | MAOB (0.84) | MAOBCYP19A1MIFMAOAACHE | |
| SCHEMBL6990912 | 0.81 | MAOB (0.84) | MAOBCYP19A1MIFMAOAACHE | |
| SCHEMBL6361474 | 0.81 | MAOB (0.67) | MAOBCYP19A1MIFMETAP1MAOA | |
| SCHEMBL6361472 | 0.81 | MAOB (0.67) | MAOBCYP19A1MIFMETAP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933392-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-08-23 | — | — | US | disclosed |
| US-6884816-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-26 | — | — | US | disclosed |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | MAY JESSE A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2003-09-25 | — | — | US | disclosed |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2003-05-01 | — | — | US | disclosed |
| EP-0700905-B1 | Tricyclic pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-5561150-A | 1-AMINOALKYL-1,4-DIHYDROINDENO(2,1-C)PYRAZOLES OR 1H-BENZ(G)INDAZOLES; SEROTONIN RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM, PSYCHOLOGICAL AND GASTROINTESTINAL DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0700905-A1 | Tricyclic pyrazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | MAOB 955/4885CYP19A1 155/4885MIF 1874/4885 |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | MAOB 955/4885CYP19A1 155/4885MIF 1874/4885 |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | MAOB 955/4885CYP19A1 155/4885MIF 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.